Regarding TLR signaling, IRAK4 inhibitors show activity in preclinical studies in ABC‐DLBCL cell lines144 and PDXs.215 A phase 1b clinical trial of one such compound is currently underway.215 JAK2 inhibitors, which are commonly used to treat myelofibrosis, are being tested in clinical trials for diverse lymphoma subtypes. The gene discussed is JAK2; the disease is myelofibrosis.